Boehringer teams up with Gubra to develop second obesity treatment

30-05-2019

Boehringer teams up with Gubra to develop second obesity treatment

nitpicker / Shutterstock.com

German pharmaceutical company Boehringer Ingelheim has entered into a second licence and collaboration agreement with Danish biotech company Gubra for the development of an obesity treatment.


Boehringer Ingelheim, Gubra, obesity, peptide poly-adonists, licence and collaboration, research and development

LSIPR